Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579750 | 0.89 | DGAT1 (0.42) | NPC1RAB9ADGAT1KDRABL1 | |
| SCHEMBL3573050 | 0.88 | GRIK1 (0.41) | SMN1; SMN2NPC1RAB9AMAPTHTT | |
| SCHEMBL3584115 | 0.88 | PSEN1 (0.45) | SMN1; SMN2NPC1RAB9AMAPTPOLB | |
| SCHEMBL3573189 | 0.87 | CNR1 (0.43) | MEN1KMT2APLK4AURKBKDR | |
| SCHEMBL3584713 | 0.85 | MTOR (0.41) | MAPTPLK4AURKBKDRABL1 | |
| SCHEMBL5467374 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AMAPTHTT | |
| SCHEMBL3577952 | 0.81 | CNR1 (0.43) | RAB9AMAPTHTTMEN1KMT2A | |
| SCHEMBL3576183 | 0.81 | KDR (0.44) | MAPTPLK4AURKBKDRAURKA | |
| SCHEMBL5474886 | 0.80 | GRIK1 (0.44) | SMN1; SMN2RAB9AMAPTHTTMEN1 | |
| SCHEMBL5950292 | 0.80 | MAPT (0.43) | SMN1; SMN2NPC1RAB9AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | claimed |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | NEUSEARCH A/S (DK) | 2006-08-10 | — | — | US | claimed |
| US-7691891-B2 | Diphenylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2010-04-06 | — | — | US | disclosed |
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | disclosed |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | NEUSEARCH A/S (DK) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | KCNJ2, KCNH2, KCNH3 | SMN1; SMN2 2422/4885NPC1 808/4885RAB9A 3911/4885 |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | CLIC1, CLIC4, CLCN2 | SMN1; SMN2 4510/4885NPC1 434/4885RAB9A 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.